[1] |
Schroder FH. Hormonal therapy of prostate cancer [M] // W.B. Saunders. 9th ed. Walsh Campbell’s Urology. The United States: W.B. Saunders, 2007:3280.
|
[2] |
Body JJ. Prevention and treatment of side-effects of systemic treatment: bone loss[J]. Ann Oncol,2010,21 Suppl 7:vii 180-5.
|
[3] |
Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives[J]. Oncologist,2008,13(2):187-95.
|
[4] |
Meier C, Nguyen TV, Handelsman DJ, et al. Endogenous sex hormones and incident fracture risk in older men: the dubbo osteoporosis epidemiology study[J]. Arch Intern Med,2008,168(1):47-54.
|
[5] |
Serpa Neto A, Tobias-Machado M, Esteves MA, et al. A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma[J]. BMC Urol,2010,10:9.
|
[6] |
Yang LP, Deng JH, Wang LS, et al. Influence of castration in the treatment of prostate cancinoma on bone mineral density[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi,2007,14(6):461-2.[杨柳平, 邓军洪,王良圣,等.去势治疗对前列腺癌患者骨密度的影响[J]. 中华肿瘤防治杂志,2007,14(6):461-2.]
|
[7] |
Wang W, Yuasa T, Tsuchiya N, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy[J]. Endocr Relat Cancer,2008,15(4):943-52.
|
[8] |
Lattouf JB, Saad F. Bone health in nonmetastatic prostate cancer: what’s the big deal?[J]. Curr Oncol,2010,17 Suppl 2:S49-54.
|
[9] |
Coleman RE. Risks and benefi ts of bisphosphonates[J].Br J Cancer, 20 08,98(11):1736-40.
|
[10] |
Liu YJ, Lu JY. Systematic review of the study on Bisphosphonates for the treatment of advanced prostate cancer[J]. Zhongguo Nan Ke Xue Za Zhi,2009,23(8):33-7,44. [刘永江, 陆敬义.二 磷酸盐治疗前列腺癌骨转移的系统评价[J].中国男科学杂志 20 09,23(8):33-7,44.]
|
[11] |
Montague R, Hart CA, George NJ, et al. Differential inhibition of invasion and proliferation by bisphosphonates: antimetastatic potential of Zoledronic acid in prostate cancer[J]. Eur Urol,2004,46(3):389-401.
|
[12] |
Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy[J]. J Clin Oncol,2008,26(27):4426-34.
|
[13] |
Satoh T, Kimura M, Matsumoto K, et al. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naïve prostate carcinoma[J]. Cancer,2009,115(15):3468-74.
|